CC BY-NC-ND 4.0 · Journal of Digestive Endoscopy 2020; 11(01): 24-26
DOI: 10.1055/s-0040-1712550
Commentary

COVID-19: Beyond Respiratory Tract

Anshuman Elhence
1  Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India
,
Shalimar› Institutsangaben
  

As we deal with the current pandemic of novel coronavirus disease 2019 (COVID-19), several studies have shed light on the hepatobiliary and pancreatic manifestations of the disease. What has emerged from the literature so far is that hepatobiliary involvement is relatively common, as evidenced by the large proportion of patients presenting with deranged liver enzymes. However, this seems to be clinically inconsequential in majority of patients. While it is postulated that the hit is likely to be more substantial in patients with preexisting severe liver disease and postliver transplant recipients, this is yet to be substantiated. The long-term consequences of COVID-19 infection and the drugs being used to combat it are currently unknown.

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV2) is responsible for COVID-19, closely resembles the other coronaviruses like SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). A comparison between these three coronaviruses and their effect on the hepatic, pancreatic and biliary systems is shown in [Table 1].

Table 1

Comparison of the coronaviruses

SARS-CoV

MERS-CoV

SARS-CoV2

Abbreviations: ACE2, angiotensin converting enzyme-2; CoV, coronavirus; COVID-19, novel coronavirus disease 2019; DPP4, dipeptidyl peptidase 4; MERS, Middle Eastern respiratory syndrome; SARS, severe acute respiratory syndrome.

Disease

SARS

MERS

COVID-19

Year of spread

2002–2003

2012

2019–2020

Homology to SARS-CoV2 genome (%)

82

50

100

Intermediate host

Palm civets

Dromedary camels

Pangolins

Route of transmission

Droplet, contact

Contact

Droplet, contact

Receptor for virus

ACE-2

DPP-4

ACE-2

Mortality (approximate %)

10

33

2–10

Evidence of liver injury-elevated enzymes (%)

60

30

14–53

Direct hepatotoxicity/inclusions

Present

Absent

Unknown

Demonstration of viral nucleic acid in hepatocytes

+

Drugs implicated in hepatotoxicity

Ribavirin, macrolides, steroids

Lopinavir/ritonavir, steroids, macrolides, remdesivir, tocilizumab

Worse outcomes in viral hepatitis

+

Unknown

Biliary system

+

+

Pancreas

+

+

We are learning in real-time every day about the clinical presentations, drug trials, and outcomes of COVID-19. In this issue, Singla and Arora extensively described the hepatobiliary and pancreatic manifestations of COVID-19.[1] The clinical presentations described are predominantly from China, Italy, and the United States, and vary across the studies. The manifestations described are varied. The phenotypic presentations of viral illness are affected by multiple factors including the virus and the host. Due to the paucity of data, the hepatic, pancreatic, and biliary manifestations in Indians and their clinical relevance are yet unclear.

Existing literature suggests that liver enzyme elevation is higher in more severe cases requiring intensive care admission. In a retrospective analysis, it has been shown that a higher proportion of patients with abnormal liver function received lopinavir/ritonavir as compared with those with normal liver function. Also, patients with abnormal liver function had a more extended hospital stay as compared with those with normal liver function.[2] Severe and acute hepatitis has been reported rarely. Chen et al reported one patient with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of 7,590 and 1,445 U/L, respectively.[3] Wander et al reported a COVID-19 patient with anicteric hepatitis with ALT and AST of 697 and 1,230 U/L, respectively.[4]

According to the data by a global registry of COVID-19 in patients with liver disease, so far in its fourth report, the mortality rate in 118 patients with cirrhosis (alcohol, 30%; nonalcoholic fatty liver disease [NAFLD], 16%; hepatitis B, 12%; and hepatitis C, 10%) was 40%. In comparison, the mortality rate in 50 patients with chronic liver disease without cirrhosis was 12%, and among 37 postliver transplant recipients was 22%.[5] The causes of death and predictors of outcome in these patients with underlying cirrhosis are not clear, but this might be due to the cytokine storm stirred by the virus leading to multiorgan failures similar to acute-on-chronic liver failure (ACLF). Drug-induced liver injury (DILI) remains an important cause of liver injury in these patients. With no currently approved therapy, several new drugs are being tested, which have well-known hepatotoxicities, concerns of exacerbating liver diseases, and interactions with other drugs given to patients with liver disease ([Table 2]). It is also not clear if changing immunosuppression among autoimmune hepatitis and postliver transplant patients may alter the risk and outcomes of COVID-19.

Table 2

Important drugs under trial for COVID-19 and their effect on liver

Serial no.

Drug

Mechanism of Action

Comments about Liver Safety

Abbreviations: ACE-2, angiotensin-converting enzyme-2; CoV, coronavirus; COVID-19, novel coronavirus disease 2019; IFN, interferon; IL, interleukin; JAK, janus kinase; mTOR, mammalian target of rapamycin; SARS, severe acute respiratory syndrome; STAT, signal transducer and activator of transcription.

1

Hydroxychloroquine (HCQ) and chloroquine (CQ)

Inhibition of viral entry via ACE-2 and interference with endosomal acidification

Hepatotoxicity is rare with HCQ

Possible drug interactions with immunosuppressive drugs

2

Azithromycin

Immunomodulatory action to inhibit virus

Significant drug interactions

Self-limiting cholestatic hepatitis

3

Lopinavir/ritonavir

Inhibits coronavirus replication by binding to Mpro, a protein critical to its replication.

Elevation in liver enzymes.

Significant drug interaction with calcineurin and mTOR inhibitors

4

Remdesivir

Adenosine analog which inhibits RNA dependent RNA polymerase

Sparse data available, however concern for hepatotoxicity exist

5

Favipiravir

RNA dependent RNA polymerase inhibitor

Risk of hepatitis

6

Tocilizumab/sarilumab/siltuximab

Monoclonal antibody against IL-6 receptor

Risk of hepatotoxicity and exacerbation of viral hepatitis

7

IFN-α

Immunomodulator

Contraindicated in patients with decompensated liver disease

8

Ribavirin

Guanosine analog which inhibits inosine monophosphate dehydrogenase

May exacerbate hemolysis and lead to jaundice by causing indirect hyperbilirubinemia

9

Anakinra

Recombinant IL-1 receptor antagonist

No risk of hepatotoxicity or exacerbation of viral hepatitis

10

Convalescent plasma

Antibodies directed against SARS-Cov2

Risk of transmission of viral hepatitis via plasma

11

Baricitinib

Janus kinase inhibitor inhibits cytokine signaling via the JAK-STAT pathway

High risk of reactivation of viral hepatitis

Elevated amylase has been reported in COVID-19; its significance is unclear. Liu et al in a series of 121 COVID-19 patients reported pancreatic injury in the form of increased lipase in 11 (16%), and imaging alterations in the form of focal head enlargement and duct dilatation in 5 (7.4%) out of 67 patients with severe COVID-19 disease; however, pancreatic necrosis was not seen in any patient.[6]

Importantly, as we gain more insight about the hepatobiliary manifestations of COVID-19, the hepatologists, gastroenterologists, and gastrointestinal (GI) surgeons must not take a backseat. We should remain aware that patients with cirrhosis and COVID-19 have high mortality, close to 40%,[5] similar to patients with ACLF.[7] We must also keep a keen eye on the hepatosafety of the new drugs under development for COVID-19.

India is a young country with a high prevalence of diabetes, hypertension, and coronary artery disease. These comorbidities have been reported to be associated with poor outcomes in COVID-19. As per a study by Mukherjee et al, the burden of chronic liver disease in India is high, and it accounts for 1.28% of patients presenting to hospital, and hence at risk of nosocomial transmission.[8] NAFLD prevalence in India is as high as 9 to 30%. These patients might be at risk of adverse outcomes from COVID-19 because of associated risk factors for severe disease such as diabetes, hypertension, and cardiac comorbidity. Indian Council of Medical Research (ICMR) has a national registry of COVID-19 which will help in understanding the manifestations of COVID-19 in India. The effect of COVID-19 on the underlying liver disease and vice versa remains unanswered at present. Several new drugs and experimental therapies are being tried. We hope that these issues can be better understood as more information pours in, and we are better prepared for the future.



Publikationsverlauf

Publikationsdatum:
16. Mai 2020 (online)

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India